why C4 Therapeutics Inc [CCCC] is a Good Choice for Investors After New Price Target of $16.50

C4 Therapeutics Inc [NASDAQ: CCCC] price surged by 21.38 percent to reach at $1.55. The company report on February 22, 2024 at 7:00 AM that C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights.

CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Phase 1 Dose Escalation Trials for CFT7455 and CFT1946 Continue to Progress; Data from Both Trials Expected in 2H 2024.

The one-year CCCC stock forecast points to a potential upside of 46.67. The average equity rating for CCCC stock is currently 1.50, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on C4 Therapeutics Inc [CCCC]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CCCC shares is $16.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CCCC stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

JP Morgan have made an estimate for C4 Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 29, 2024. While these analysts kept the previous recommendation, Stifel dropped their target price from $2 to $12. The new note on the price target was released on December 13, 2023, representing the official price target for C4 Therapeutics Inc stock. Previously, the target price had yet another drop from $12 to $10, while Credit Suisse kept a Neutral rating on CCCC stock. On February 24, 2023, analysts decreased their price target for CCCC shares from 15 to 5.

The Average True Range (ATR) for C4 Therapeutics Inc is set at 0.72, with the Price to Sales ratio for CCCC stock in the period of the last 12 months amounting to 21.31. The Price to Book ratio for the last quarter was 2.01, with the Price to Cash per share for the same quarter was set at 4.39.

CCCC Stock Performance Analysis:

C4 Therapeutics Inc [CCCC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.38. With this latest performance, CCCC shares gained by 56.03% in over the last four-week period, additionally plugging by 170.77% over the last 6 months – not to mention a rise of 53.04% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CCCC stock in for the last two-week period is set at 70.04, with the RSI for the last a single of trading hit 73.83, and the three-weeks RSI is set at 67.72 for C4 Therapeutics Inc [CCCC]. The present Moving Average for the last 50 days of trading for this stock 5.91, while it was recorded at 7.90 for the last single week of trading, and 3.45 for the last 200 days.

Insight into C4 Therapeutics Inc Fundamentals:

C4 Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.39 and a Current Ratio set at 7.39.


With the latest financial reports released by the company, C4 Therapeutics Inc posted -0.77/share EPS, while the average EPS was predicted by analysts to be reported at -0.74/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -4.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CCCC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for C4 Therapeutics Inc go to 22.30%.

C4 Therapeutics Inc [CCCC] Institutonal Ownership Details

The top three institutional holders of CCCC stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in CCCC stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in CCCC stock with ownership which is approximately 5.8325%.